E85.8
Other amyloidosis
Clinical Classification Guidelines
Medical Intelligence & Overview
Other amyloidosis is a rare form of amyloidosis characterized by the abnormal build-up of amyloid proteins in various tissues and organs of the body. This condition is distinct from more common types such as AL amyloidosis or AA amyloidosis, and it can affect different parts of the body, leading to varied health issues. The form classified under ICD-10 Code E85.8 encompasses these less common amyloid deposits that do not fit into the main categories, making diagnosis and management a specialized process.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal amyloid protein production Chronic inflammatory conditions, although less frequently associated with this specific subtype Age-related changes in protein processing Certain rare inherited or acquired conditions that cause abnormal protein folding Unknown triggers in some cases, where no specific cause is identified
Key Symptoms: Swelling or enlargement of affected tissues or organs Unexplained fatigue and weakness Organ-specific symptoms based on lymphatic and tissue involvement Skin changes such as rash or easy bruising (if skin is involved) Difficulty breathing or shortness of breath (if lungs are affected) Digestive issues like bloating, diarrhea, or weight loss (if gastrointestinal tract is involved) Impaired organ function, potentially leading to complications such as kidney or heart failure
Diagnostic & Treatment
Diagnosis Path: Medical history review and physical examination to identify organ enlargement or tissue changes Blood and urine tests to detect abnormal proteins and assess organ function Biopsy of affected tissue to confirm amyloid deposits via specialized staining techniques Imaging tests such as ultrasound, MRI, or CT scans to evaluate organ involvement Advanced diagnostic procedures including mass spectrometry for precise protein identification
Treatment Protocols: Therapies aimed at managing symptoms and preventing organ damage Chemotherapy or immunotherapy in cases where amyloidosis is linked to abnormal plasma cell activity Supportive treatments like diuretics for swelling, or medications for organ performance Potential use of novel agents designed to stabilize or promote clearance of amyloid proteins Regular monitoring of organ function to adapt treatment plans accordingly In some cases, stem cell transplantation may be considered for select patients
Clinical Advice & FAQs
Billing Guidance
Is E85.8 a billable ICD-10 code?
Yes, E85.8 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E85.8?
Clinical documentation must specify the nature of Other amyloidosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference